Explore the SOSTOS Clinical Trial: Advancing MS Treatments in Arizona
Are you living with relapsing-remitting multiple sclerosis (RRMS) and stable on treatment for the past 6 months? The SOSTOS Study is now enrolling participants in Arizona and nearby states to explore whether switching treatments can better protect against underlying nervous system damage in MS patients. Join us at Arizona Neuroscience Research and contribute to cutting-edge advancements in MS care.
About the SOSTOS Study
The SOSTOS clinical trial is investigating the safety and potential benefits of switching to an investigational therapy called ofatumumab (already approved for MS) compared to continuing current MS treatments. This study also focuses on neurofilament light (NfL), a biomarker that could help detect nervous system decline early, even when no new relapses occur.
Why is this important?
Many MS patients experience underlying nerve damage despite being relapse-free. By identifying changes in NfL levels, researchers aim to understand if switching to ofatumumab can better protect against silent disease progression.
Why Participate?
- Contribute to MS Research: Your participation can help advance treatments that may prevent long-term disability in MS.
- Cutting-Edge Monitoring: Participants will receive advanced care, including MRI scans and biomarker analysis, at no cost.
- Access Expert Care: Work closely with experienced neurologists and MS researchers in Arizona.
Who Can Join?
You may qualify if you:
- Are 18–45 years old
- Have a confirmed diagnosis of RRMS
- Have been on a stable MS treatment for at least 6 months
- Have not had a relapse in the past 6 months
- Are willing to wear a study watch to monitor physical activity, sleep, and vitals
What to Expect During the Study
The study will last approximately 22 months and includes 12 study visits. It consists of four phases:
- Screening (1 week): Initial tests to confirm eligibility.
- Run-In Period (6 months): Participants remain on their current treatment, with a chance to wear a study watch for activity monitoring.
- Treatment Period (up to 15 months):
- Participants will be randomly assigned to either:
- Switch to ofatumumab (study drug)
- Continue their current treatment
- Regular clinic visits and some remote check-ins (phone or video).
- Participants will be randomly assigned to either:
- Follow-Up (4 weeks): Final safety evaluations and check-ins.
Why Arizona is the Ideal Location for MS Research
Arizona’s advanced clinical research facilities make it a hub for MS innovation. With access to world-class neurologists and cutting-edge studies like SOSTOS, residents of Arizona and neighboring states—such as California, Nevada, New Mexico, and Utah—have a unique opportunity to shape the future of MS care.
Why NfL Matters
This study focuses on neurofilament light (NfL), a promising biomarker that can detect nerve damage early. By monitoring NfL, researchers aim to determine when switching treatments can make a real difference in protecting against future disability.
How to Join
To learn more about the SOSTOS Study and see if you qualify, visit:
👉 AZNeuroscienceResearch.com
You can also contact our study team directly to discuss eligibility and next steps.
Spread the Word
If you or someone you know is living with relapsing MS, take the next step toward advancing MS care. Join the SOSTOS Study and help pave the way for improved treatment strategies.
#Hashtags to Share
#MSResearch #ArizonaClinicalTrials #RelapsingMS #SOSTOSStudy #MSAwareness #NeurologyResearch #AZNeuroscience #ClinicalTrialsAZ
Visit AZNeuroscienceResearch.com today to learn how you can participate!
